Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

<p>Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase 3 Study Design Partnership Discussions Remain Ongoing for MAT2203 BEDMINSTER, N.J., Dec. 21, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. […]</p>
<p>The post <a href="https://forextv.com/top-news/matinas-biopharma-provides-update-to-mat2203-regulatory-and-development-pathway-following-feedback-from-fda/">Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>